Scientists Analyze 267 Receptors That Control Protein Fate in Rare Diseases

Researchers from the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) say they have created the first systematic catalog of the substrate receptors of cullin–RING ligases and analyzed how their genetic variants may translate into disease symptoms. Their review article “Cullin-RING receptors in rare disease biology” appears in Trends in Cell Biology

“In rare diseases, we often identify a variant in a particular gene without immediately understanding its biological consequences. Our work shows that when such a variant affects a substrate receptor, it can disrupt protein recognition, impair the ligase complex, or disturb other cellular processes important for the organism’s development and function. This makes it easier to connect a genetic change with the disease mechanism and understand why it leads to particular symptoms,” said Wojciech Pokrzywa, PhD, head of the laboratory of protein metabolism at IIMCB.

Cells constantly control the fate of their proteins. They remove proteins that are worn out or no longer needed, but can also alter their activity, localization, or interactions with other molecules. The ubiquitin–proteasome system plays a key role in this process. Its enzymes tag selected proteins with ubiquitin, which acts as a molecular label. Depending on the type of tag, a protein may be directed for degradation by the proteasome—the cell’s molecular “shredder”—or subjected to another form of regulation.

Cullin–RING ligases belong to the largest family of E3 enzymes responsible for attaching these tags. Their precision depends on substrate receptors, which recognize the specific proteins that the ligase acts upon. The IIMCB scientists focused their work on the role of these receptors in genetic diseases

The authors combined data on receptors’ function, tissue expression, and associations with different types of disease. They found that neurodevelopmental and neuromuscular symptoms are particularly common in diseases linked to these receptors, even though most of the receptors do not clearly show tissue-specific expression

Their analyses therefore indicate that the clinical presentation cannot be explained solely by the sites of protein expression. Instead, other important factors may include the substrates they recognize, gene activity at different stages of development, the vulnerability of particular cell types, gene dosage, and the effect of a specific variant on the function of the entire cullin–RING ligase complex

267 receptors, 93 linked to genetic diseases 

“We created the first systematic catalog of 267 cullin–RING ligase substrate receptors, 93 of which have already been linked to genetic diseases. This rees and the ubiquitin–proteasome system,” noted Natalia Szulc, a PhD student in the laboratory of protein metabolism at IIMCB and the first author of the article

“It can help identify further potential disease genes and interpret variants detected in patients. It also facilitates studies into why different mutations in the same gene can produce different symptoms and disease courses. The catalog may also help reconstruct networks of relationships between receptors, their substrates, and other ligases, which is important for understanding why cells can sometimes compensate for the effects of a mutation, while in other cases disease develops.”

Targeted protein degradation is now an important direction in the development of new therapies, Pokrzywa added

“Rare diseases show how precisely the ubiquitin–proteasome system must operate: altering a single component can have serious consequences that emerge only in particular tissues or at specific stages of development,” Szulc said

“By analyzing variants found in patients, we can better understand which features of substrate receptors determine the function of cullin–RING complexes, which substrate interactions might be amenable to modulation, and where the limitations of therapies based on targeted protein degradation may lie. This provides valuable guidance for designing safer and more precise therapeutic strategies,” said Pokrzywa